EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization

Diagnostic Cytopathology

Volumn 33, Issue 4, 2005, Pages 228-232

  Sauer, Torill ^a   Beraki, Kahsai ^a   Noren, Tove ^a   Garred, Øystein ^a   Næss, Oddvar ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Amplification; Breast carcinoma; CISH; EGFR; In situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; ASPIRATION CYTOLOGY; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN; CELL STRAIN MCF 7; CELL STRAIN SKBR2; CELL STRAIN T47D; CENTROMERE; CHROMOGENIC IN SITU HYBRIDIZATION; CHROMOSOME 7; CHROMOSOME 7 CENTROMERE PROBE; CLINICAL ARTICLE; EGFR GENE; GENE; GENE AMPLIFICATION; GENE COPY LOSS; GENE COPY NUMBER; GENE LOSS; GENE NUMBER; GENE OVEREXPRESSION; HIGH DOSAGE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MOLECULAR PROBE; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR CELL LINE;

EID: 25444510347     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20338     Document Type: Article

References (59)

1. Dabbs DJ. Correlation of morphology, proliferation indices, and oncogene activation in ductal breast carcinoma: nuclear grade, S-phase, proliferating nuclear antigen, p53, epidermal growth factor receptor, and c-erbB-2. Mod Pathol 1995;8:637-642.
2. Seshadri R, McLeay WRB, Horsfall DJ, McCaul K. Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer 1996;69:23-27.
3. Cerra M, Cecco L, Montella M, Tucillo F, Bonelli P. Epidermal growth factor receptor in human breast cancer: comparison with steroid receptors and other prognostic factors. Int J Biol Markers 1995;10(3):136-142.
4. Beckmann MW, Niederacher D, Massenkeil G, et al. Expression analysis of epidermal growth factor receptor and HER-2/neu: no advantage of prediction of recurrence or survival in breast cancer patients. Oncology 1996;53:441-447.
5. Eissa S, Khalifa A, el-Gharib A, Salah N, Mohamed MK. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer. Anticancer Res 1997;17:1417-1423.
6. Gupta GR, Datta BN, Bose SM, Joshi K. Correlation of growth fraction, nucleolar organizer region counts and epidermal growth factor receptor with histomorphological prognostic criteria in breast cancer. Indian J Pathol Microbiol 1997;40:3-10.
7. Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interaction with neu. J Steroid Biochem 1989;34:123-131.
8. Hawkins RA, Tesdale AL, Killen ME, Jack WJ, Chetty U, Dixon JM. Prospective evaluation of prognostic factors in operable breast cancer. Br J Cancer 1996;74:1469-1478.
9. Ioachim E, Kamina S, Athanaaaiadou S, Agnatis NJ. The prognostic significance of epidermal growth factor receptor (EGFR), e-erbB-2, Ki-67 and PCNA expression in breast cancer. Anticancer Res 1996;16:3141-3147.
10. Iwase H, Itoh Y, Kuzushima T, Yamashita H, Iwata H, Toyama T. Simultaneous quantitative analysis of c-erbB-2 protein, epidermal growth factor receptor, catepsin D, and hormone receptors in breast cancer. Cancer Detect Prev 1997;21:29-35.
11. Koenders P, Beex L, Kienhuis C, Kloppenborg P, Beraad T. Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 1992;23:134
12. Koutselini H, Markopoulos CH, Lambropoulou S, Gogas H, Kandaraki CH, Gogas J. Relationship of epidermal growth factor receptor (EGFR). proliferating cell nuclear antigen (PCNA) and vimentin expression and various prognostic factors in breast cancer patients. Cytopathology 1995;6:14-21.
13. Lee CS, deFazio A, Ormandy CJ, Sutherland RL. Inverse regulation of oestrogen receptor and epidermal growth factor receptor gene expression in MCF-7 breast cancer cells treated with phorbol ester. J Steroid Biochem Mol Biol 1996;58:267-275.
14. Pirinen R, Lipponen P, Syrjanen K. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors. Anticancer Res 1995;15:2835-2840.
15. Sainsbury JRC, Farndon JR, Needham GK. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987;1:1398-1402.
16. Schroeder W, Biesterfeld S, Zillessen S, Rath W. Epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 1997;17:2799-2802.
17. Torregrosa D, Bolufer P, Lluch A, Barragan E, Ruiz A, Guillem V. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta 1997;262:99-119.
18. van Agthoven T, Timmermans M, Dorssers LC, Henzen-Logmans SC. Expression of estrogen, progesterone and epidermal growth factor receptors in primary and metastatic breast cancer. Int J Cancer 1995;63:790-793.
19. Travers MT, Barret-Lee PJ, Berger U, Luqmani YA, Gazet JC, Powles TJ. Growth factor expression in normal, benign and malignant breast tissue. BMJ 1988;296:1621-1624.
20. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47:87-98.
21. Modi S, Hudis CA. Signal transduction inhibitors as novel anticancer agents in the treatment of breast cancer. Breast Cancer Online 2002;5:1-7.
22. Nahta R, Hortobagyi GN, Esteva FJ. Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 2003;8:5-17.
23. Wang Y, Minoshima S, Shimizu N. Precise mapping of the EGFR receptor gene on the human chromosome 7p12 using an improved FISH technique. Jpn J Hum Genet 1993;38:399-406.
24. Briand P, Nielsen KV, Madsen MW, Petersen OW. Trisomy 7 and malignant transformation of human epithelial cells following epidermal growth factor withdrawal. Cancer Res 1996;56:2039-2044.
25. Bieche I, Champene MH, Matifas F, Hacene K, Callahan R, Lidereau R. Loss of heterocygocity on chromosome 7q and aggressive primary breast cancer. Lancet 1992;339:139-143.
26. Champene MH, Bieche I, Beuzeelin M, Lidereau R. Loss of heterocygocity on 7q31 occurs early during breast tumorigenesis. Genes Chrom Cancer 1995;12:304-306.
27. Devilee P, Hermans J, Eyfjord J, Børresen A-L, Lidereau R, Sobol H. Loss of heterozygosity at 7q31 in breast cancer: results from an International Collaborative Study Group. The Breast Cancer Somatic Genetics Consortium. Genes Chrom Cancer 1997;18(3):193-199.
28. Kristiansson AK, Eiriksdottir G, Ragnarsson G, Sigurdsson A, Gudmundsson I, Barkardottir RB. Loss of heterozygosity at chromosome 7q in human breast cancer: association with clinical variables. Anticancer Res 1997;17:93-98.
29. Sauer T, Beraki K, Jebsen PW, Ormerod E, Næss O. Ploidy analysis by in situ hybridization of interphase cell nuclei in fine-needle aspirates from breast carcinomas: correlation with cytologic grading. Diagn Cytopathol 1997;17:267-271.
30. Sauer T, Beraki K, Jebsen PW, Ormerod E, Næss O. Numerical abnormalities of chromosome 7 in interphase celle nuclei from breast carcinoma cells have no impact on immunohistochemically determined EGFR status. APMIS 1999;107:211-216.
31. Davidson S, Gelman EP, Lippman ME, Dickson RB. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1987;1:216-233.
32. King CR, Kraus MH, Williams L-T, Merlino GT, Pata IH, Aaronsen SA. Human tumor cell lines with EGF receptor gene amplification in the absence of aberrant sized mRNAs. Nucl Acids Res 1985;13:8477-8486.
33. Xu YH, Richert N, Oti S, Merlino GT, Pastan I. Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc Natl Acad Sci U S A 1984;81:7308-7312.
34. Hudson LG, Santon JB, Gill GN. Regulation of epidermal growth factor receptor gene expression. Mol Endocrinol 1989;3:400-408.
35. Yarden RI, Lauber AH, El-Ashry D, Chrysogeles SA. Bimodal regulation of epidermal growth factor receptor by estrogen in breast cancer cells. Endocrinology 1996;137:2739-2747.
36. Schlegel J, Merdes A, Stumm G, Albert FK, Forsting M, Hynes N. Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behaviour in human glioblastoma. Int J Cancer 1994;65:72-77.
37. Al-Kasspooles M, Moore JH, Orringer MB, Beer DG. Amplification and over-expression of the EGFR and c-erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 1993;54:213-219.
38. deFazio A, Chiew YE, McEvoy M, Watts CK. Antisense estrogen receptor RNA expression increases epidermal growth factor receptor gene expression in breast cancer cells. Cell Growth Differ 1997;8(8):903-911.
39. Ishikawa J, Maeda S, Umezu K, Sugiyama T, Kamidono S. Amplification and overexpression of the epidermal growth factor gene expression in human renal-cell carcinoma. Int J Cancer 1990;45:1018-1021.
40. Joos S, Scherthan H, Speicher MR, Schlegel J, Cremer T, Lichter P. Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe. Hum Genet 1993;90:584-589.
41. Sauter G, Maeda S, Waldman FM, Davis RL, Feuerstein BG. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am J Pathol 1996;148:1047-1053.
42. Sauer T, Beraki K, Furu I, Ormerod E, Jebsen PW, Næss O. Estimating loss of the wild-type p53 gene by in situ hybridization of fine-needle aspirates from breast carcinomas. Diagn Cytopathol 1999;20:266-270.
43. Kersting C, Tidow N, Schmidt H, et al. Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of EGFR amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 2004;84:582-587.
44. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
45. Marquez A, Wu R, Zhao J, Tao J, Shi Z. Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy. Diagn Mol Pathol 2004;13:1-8.
46. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904.
47. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
48. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
49. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sakaria I. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefinitib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
50. Butt AJ, Martin JL, Dickson KA, McDougall F, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling. J Clin Endocrinol Metab 2004;89:1950-1956.
51. Couturier J, Vincent-Salmon A, Nicolas A, et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Mod Pathol 2000;13:1238-1243.
52. Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E. Correlation between immunohistochemistry (Herceptest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003;199:418-423.
53. Gancberg D, Lespagnard L, Rouas G, et al. Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Anatomic Pathol 2000;113:675-682.
54. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000;19:6102-6114.
55. Hoang MP, Sahtn AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:853-859.
56. Jacobs TW, Gown AM, Yaziji H. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974-1982.
57. Lebeau A, Deimling D, Kaltz C, et al. HER-2/neu analysis in archival tissue samples of human breast cancer, comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-363.
58. Jorissen RN, Walker F, Pouliot N, Garret TPJ, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
59. Stern DF. Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res 2000;2:176-183.